(PharmaNewsWire.Com, February 02, 2021 ) In this report, the global women health diagnostics market is segmented on the basis of application and end user. On the basis of application, the market is segmented into nine segments namely, osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound. The osteoporosis segment is further divided into bone densitometry and in vitro blood tests.
Major Growth Drivers:
Factors such as growing awareness about various health-related disorders among women, rising incidence of various chronic and lifestyle disorders in women, and high prevalence of infectious diseases such as HIV and hepatitis in women across the globe are driving the growth of the market. Moreover, the increasing adoption of point-of-care diagnostic testing and the increasing number of diagnostic and imaging centers are also expected to play a major role in market growth. However, shortage of skilled laboratory technicians and high costs of diagnostics devices, tests, and procedures are hindering the growth of women health diagnostics market.
Expected Revenue Growth:
The global women’s health diagnostics market is projected to reach USD 36.64 Billion by 2021 from USD 25.03 Billion in 2016, at a CAGR of around 7.9% during the forecast period.
Accessories to Fuel the Growth of Women’s Health Diagnostics Market :
The osteoporosis segment is further divided into bone densitometry and in vitro blood tests. The ovarian cancer segment is divided into tumor marker tests, diagnostic imaging tests and others. The cervical cancer segment is sub segmented into PAP smear testing and HPV testing. The breast cancer testing segment is further divided into mammography, tumor marker tests, blood cell count & blood chemistries, biopsies and other diagnostic imaging tests. Pregnancy and fertility testing market is sub segmented into lab-based testing, pregnancy self-test and ovulation prediction kits, ovulation prediction kits, fertility monitors and thermometers. The prenatal genetic screening & carrier testing segment is further divided into cystic fibrosis, Down syndrome and Edward syndrome, TORCH infections and others (fragile x-syndrome & tay-sachs diseases).
The global market has been segmented, on the basis of applications, and end users. On the basis of application, the market is segmented into various segments, namely, osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound. On the basis of end user, the global women health diagnostics is segmented into three segments, namely, hospital and clinics, home healthcare, and diagnostic & imaging centers.
In 2015, the breast cancer testing segment accounted for the largest share of the market. However, the prenatal genetic screening and carrier testing segment is expected to grow at a higher CAGR during the forecast period. This growth can be attributed to factors such as the growing number of doctors offering genetic screening tests to pregnant women and growing awareness about these tests.
Further on, the infectious disease testing market segment is sub segmented into methicillin-resistant staphylococcus aurea (MRSA), urinary tract infections (vaginal pH & vaginitis), hepatitis, tuberculosis, and others infectious disease testing. The sexually transmitted disease testing segment comprises Chlamydia Trachomatis and Neisseria Gonorrohoeae testing, HIV testing and other STD testing.. The ultrasound segment covers breast imaging and ob/gyn imaging. On the basis of end user, the market is segmented into hospitals & clinics, home care, and diagnostic & imaging centers.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2015, North America commanded the largest share, followed by Europe, Asia-Pacific, and the RoW. Asia-Pacific represented the fastest-growing region for the women health diagnostics market during the forecast period, primarily due to improving healthcare infrastructure, growing per capita income, growing awareness among women regarding various health disorders, and rising focus of key market players on this region.
Key players in the Women’s Health Diagnostics Market :
Major players in the global women’s health diagnostics market are Siemens AG (Germany), Quest Diagnostics Inc. (U.S.), Hologic, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), PerkinElmer Inc. (U.S.), Alere Inc. (U.S.), GE Healthcare (U.S.), Becton, Dickinson and Company (BD) (U.S.), Abbott Laboratories (U.S.), bioMérieux SA (France), and Koninklijke Philips N.V. (Netherlands).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
